Research programme: transplant rejection therapeutics - IcagenAlternative Names: Ion channel modulators research programme - ICAgen
Latest Information Update: 11 Feb 2008
At a glance
- Originator Icagen
- Class Small molecules
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 11 Dec 1998 New profile
- 11 Dec 1998 Preclinical development for Transplant rejection in USA (Unknown route)